Effects of Serial Ketamine Infusions on Corticolimbic Functional Connectivity in Major Depression.
Antidepressant treatment
Functional connectivity
Ketamine
Major depression
Mood disorders
Personalized medicine
Journal
Biological psychiatry. Cognitive neuroscience and neuroimaging
ISSN: 2451-9030
Titre abrégé: Biol Psychiatry Cogn Neurosci Neuroimaging
Pays: United States
ID NLM: 101671285
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
received:
08
06
2020
revised:
25
06
2020
accepted:
26
06
2020
pubmed:
10
9
2020
medline:
17
7
2021
entrez:
9
9
2020
Statut:
ppublish
Résumé
Ketamine is a highly effective antidepressant for patients with treatment-resistant major depressive disorder (MDD). Resting-state functional magnetic resonance imaging studies show disruptions of functional connectivity (FC) between limbic regions and resting-state networks (RSNs) in MDD, including the default mode network, central executive network (CEN), and salience network (SN). Here, we investigated whether serial ketamine treatments change FC between limbic structures and RSNs. Patients with MDD (n = 44) were scanned at baseline (time 1 [T1]) and 24 hours after the first (T2) and fourth (T3) infusions of ketamine. Healthy control subjects (n = 50) were scanned at baseline, with a subgroup (n = 17) being rescanned at 2 weeks. Limbic regions included the amygdala and hippocampus, and RSNs included the default mode network, CEN, and SN. Ketamine increased right amygdala FC to the right CEN (p = .05), decreased amygdala FC to the left CEN (p = .005) at T2 versus T1 (p = .015), which then increased at T3 versus T2 (p = .002), and decreased left amygdala FC to the SN (p = .016). Decreased left amygdala to SN FC at T2 predicted improvements in anxiety at T3 (p = .006). Ketamine increased right hippocampus FC to the left CEN (p = .001), and this change at T2 predicted decreased anhedonia at T3 (p = .005). Ketamine modulates FC between limbic regions and RSNs implicated in MDD. Increases in FC between limbic regions and the CEN suggest that ketamine may be involved in restoring top-down control of emotion processing. FC decreases between the left amygdala and SN suggest that ketamine may ameliorate MDD-related dysconnectivity in these circuits. Early FC changes between limbic regions and RSNs may be predictive of clinical improvements.
Sections du résumé
BACKGROUND
Ketamine is a highly effective antidepressant for patients with treatment-resistant major depressive disorder (MDD). Resting-state functional magnetic resonance imaging studies show disruptions of functional connectivity (FC) between limbic regions and resting-state networks (RSNs) in MDD, including the default mode network, central executive network (CEN), and salience network (SN). Here, we investigated whether serial ketamine treatments change FC between limbic structures and RSNs.
METHODS
Patients with MDD (n = 44) were scanned at baseline (time 1 [T1]) and 24 hours after the first (T2) and fourth (T3) infusions of ketamine. Healthy control subjects (n = 50) were scanned at baseline, with a subgroup (n = 17) being rescanned at 2 weeks. Limbic regions included the amygdala and hippocampus, and RSNs included the default mode network, CEN, and SN.
RESULTS
Ketamine increased right amygdala FC to the right CEN (p = .05), decreased amygdala FC to the left CEN (p = .005) at T2 versus T1 (p = .015), which then increased at T3 versus T2 (p = .002), and decreased left amygdala FC to the SN (p = .016). Decreased left amygdala to SN FC at T2 predicted improvements in anxiety at T3 (p = .006). Ketamine increased right hippocampus FC to the left CEN (p = .001), and this change at T2 predicted decreased anhedonia at T3 (p = .005).
CONCLUSIONS
Ketamine modulates FC between limbic regions and RSNs implicated in MDD. Increases in FC between limbic regions and the CEN suggest that ketamine may be involved in restoring top-down control of emotion processing. FC decreases between the left amygdala and SN suggest that ketamine may ameliorate MDD-related dysconnectivity in these circuits. Early FC changes between limbic regions and RSNs may be predictive of clinical improvements.
Identifiants
pubmed: 32900657
pii: S2451-9022(20)30169-5
doi: 10.1016/j.bpsc.2020.06.015
pmc: PMC8629108
mid: NIHMS1610253
pii:
doi:
Substances chimiques
Ketamine
690G0D6V8H
Banques de données
ClinicalTrials.gov
['NCT02165449']
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
735-744Subventions
Organisme : NIMH NIH HHS
ID : F32 MH111193
Pays : United States
Organisme : NIMH NIH HHS
ID : K24 MH102743
Pays : United States
Organisme : NIMH NIH HHS
ID : U01 MH110008
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2020 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.
Références
JAMA Psychiatry. 2013 Apr;70(4):373-82
pubmed: 23389382
J Neurosci. 2007 Aug 15;27(33):8877-84
pubmed: 17699669
J Affect Disord. 2018 Jan 1;225:539-544
pubmed: 28866298
Neurosci Biobehav Rev. 2018 Jan;84:272-288
pubmed: 28859997
Behav Brain Res. 2009 Aug 12;201(2):239-43
pubmed: 19428640
Nat Rev Neurosci. 2015 Jan;16(1):55-61
pubmed: 25406711
Biol Psychiatry. 2016 Feb 15;79(4):282-92
pubmed: 25842202
J Affect Disord. 2016 Jan 15;190:836-841
pubmed: 26630613
Biol Psychiatry. 2018 Oct 15;84(8):582-590
pubmed: 29580569
Front Psychiatry. 2018 Mar 15;9:83
pubmed: 29599728
Biol Psychiatry. 2013 Aug 15;74(4):250-6
pubmed: 22840761
Hum Brain Mapp. 2020 May;41(7):1699-1710
pubmed: 32115848
Brain Imaging Behav. 2017 Dec;11(6):1604-1615
pubmed: 27744495
Biol Psychiatry. 2006 Jun 15;59(12):1151-9
pubmed: 16566899
J Neuropsychiatry Clin Neurosci. 1997 Summer;9(3):471-81
pubmed: 9276848
Behav Res Ther. 1995 Mar;33(3):335-43
pubmed: 7726811
Arch Gen Psychiatry. 2006 Aug;63(8):856-64
pubmed: 16894061
Hum Brain Mapp. 2016 Sep;37(9):3214-23
pubmed: 27144347
Cogn Affect Behav Neurosci. 2017 Dec;17(6):1242-1254
pubmed: 29110183
Am J Psychiatry. 2016 Aug 1;173(8):816-26
pubmed: 27056608
Cereb Cortex. 2013 Mar;23(3):739-49
pubmed: 22437053
Neuropsychol Rev. 2012 Sep;22(3):229-51
pubmed: 22569771
J Neurosci. 2007 Feb 28;27(9):2349-56
pubmed: 17329432
Proc Natl Acad Sci U S A. 2010 Jun 15;107(24):11020-5
pubmed: 20534464
Mol Psychiatry. 2016 Jul;21(7):894-902
pubmed: 26416545
J Abnorm Psychol. 2000 Aug;109(3):504-11
pubmed: 11016119
Trends Cogn Sci. 2011 Oct;15(10):483-506
pubmed: 21908230
Arch Gen Psychiatry. 2004 Jan;61(1):34-41
pubmed: 14706942
Biol Psychiatry. 2001 Nov 1;50(9):651-8
pubmed: 11704071
Int Clin Psychopharmacol. 2010 Nov;25(6):328-33
pubmed: 20805756
Behav Res Ther. 1994 Nov;32(8):871-8
pubmed: 7993332
Biol Psychiatry Cogn Neurosci Neuroimaging. 2018 Apr;3(4):311-319
pubmed: 29628063
Neuroimage Clin. 2017 Jan 27;14:464-470
pubmed: 28275546
Am J Psychiatry. 2006 Sep;163(9):1531-41; quiz 1666
pubmed: 16946177
Trends Cogn Sci. 2010 Jun;14(6):277-90
pubmed: 20493761
J Neurosci. 2010 Nov 24;30(47):15726-34
pubmed: 21106812
Neuropsychopharmacology. 2017 May;42(6):1210-1219
pubmed: 27604566
Am J Psychiatry. 1999 May;156(5):675-82
pubmed: 10327898
Compr Psychiatry. 2015 Jan;56:29-34
pubmed: 25266848
Neurosci Biobehav Rev. 2013 Feb;37(2):152-63
pubmed: 23206667
Neuroimage. 2013 Oct 15;80:105-24
pubmed: 23668970
Eur Neuropsychopharmacol. 2019 Apr;29(4):501-508
pubmed: 30819549
J Affect Disord. 2012 Dec 10;141(2-3):194-203
pubmed: 22460056
Biol Psychiatry. 2003 Sep 1;54(5):515-28
pubmed: 12946880
J Clin Psychiatry. 2014 May;75(5):e417-23
pubmed: 24922494
Br Med Bull. 2003;65:193-207
pubmed: 12697626
Clin Psychol Rev. 2011 Feb;31(1):138-45
pubmed: 20817334
JAMA Psychiatry. 2015 Jun;72(6):603-11
pubmed: 25785575
Neuron. 2005 Mar 3;45(5):651-60
pubmed: 15748841
Psychol Med. 2020 Apr;50(6):1032-1042
pubmed: 31023398
Proc Natl Acad Sci U S A. 2009 Feb 10;106(6):1942-7
pubmed: 19171889
J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62
pubmed: 14399272
Harv Rev Psychiatry. 2018 Nov/Dec;26(6):320-339
pubmed: 29465479
Annu Rev Psychol. 1989;40:457-92
pubmed: 2648983
J Clin Psychiatry. 2001;62 Suppl 16:5-9
pubmed: 11480882
Neuroimage. 2006 Jul 1;31(3):968-80
pubmed: 16530430
Biol Psychiatry. 2010 Jan 15;67(2):139-45
pubmed: 19897179
J Affect Disord. 2018 Feb;227:280-288
pubmed: 29128784
Hum Brain Mapp. 2008 Jun;29(6):683-95
pubmed: 17598168
J Affect Disord. 2008 Nov;111(1):13-20
pubmed: 18603301
Am J Psychiatry. 2006 Jan;163(1):28-40
pubmed: 16390886
Am J Psychiatry. 2004 Apr;161(4):598-607
pubmed: 15056502
Biol Psychiatry. 2014 Aug 1;76(3):258-66
pubmed: 24387823
Neuroimage. 2004 May;22(1):409-18
pubmed: 15110034
Cereb Cortex. 2015 Sep 22;26(11):4337-4346
pubmed: 26400916
Trends Cogn Sci. 2012 Jan;16(1):61-71
pubmed: 22197477
Biol Psychiatry. 2019 Mar 15;85(6):466-476
pubmed: 30424864
iScience. 2020 Jan 24;23(1):100800
pubmed: 31918047
Transl Psychiatry. 2015 Feb 17;5:e509
pubmed: 25689570
J Affect Disord. 2015 Feb 1;172:8-17
pubmed: 25451389
Biol Psychiatry. 2011 Aug 15;70(4):334-42
pubmed: 21791259
Neuroscientist. 2014 Dec;20(6):652-64
pubmed: 24622818
J Psychopharmacol. 2015 May;29(5):596-607
pubmed: 25691504
Biol Psychiatry Cogn Neurosci Neuroimaging. 2016 Jan;1(1):77-86
pubmed: 26878070
Am J Psychiatry. 2013 Oct;170(10):1134-42
pubmed: 23982301
J Abnorm Psychol. 2002 Nov;111(4):589-97
pubmed: 12428772
Eur Neuropsychopharmacol. 2020 Apr;33:89-100
pubmed: 32061453
Psychiatr Serv. 2014 Aug 1;65(8):977-87
pubmed: 24789696